D. E. Shaw & Co., Inc. Cogent Biosciences, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 298,711 shares of COGT stock, worth $3.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

298,711

Previous 451,232 33.8%

Holding current value

$3.26 Million

Previous $3.03 Million 16.95%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$6.01 - $9.04 $916,651 - $1.38 Million	-152,521 Reduced 33.8%	298,711 $2.52 Million
Q1 2024 May 15, 2024	BUY	$4.38 - $9.02 $1.72 Million - $3.54 Million	392,431 Added 667.39%	451,232 $3.03 Million
Q4 2023 Feb 14, 2024	SELL	$4.06 - $10.08 $210,003 - $521,388	-51,725 Reduced 46.8%	58,801 $345,000
Q3 2023 Nov 14, 2023	SELL	$9.69 - $13.34 $887,894 - $1.22 Million	-91,630 Reduced 45.33%	110,526 $1.08 Million
Q2 2023 Aug 14, 2023	SELL	$9.85 - $13.24 $2.56 Million - $3.44 Million	-259,678 Reduced 56.23%	202,156 $2.39 Million
Q1 2023 May 15, 2023	SELL	$10.04 - $15.5 $2.73 Million - $4.21 Million	-271,626 Reduced 37.03%	461,834 $4.98 Million
Q4 2022 Feb 14, 2023	SELL	$10.65 - $14.84 $1.77 Million - $2.47 Million	-166,613 Reduced 18.51%	733,460 $8.48 Million
Q3 2022 Nov 14, 2022	BUY	$9.39 - $16.99 $6.61 Million - $12 Million	704,172 Added 359.45%	900,073 $13.4 Million
Q2 2022 Aug 15, 2022	BUY	$3.92 - $9.73 $767,931 - $1.91 Million	195,901 New	195,901 $1.77 Million
Q1 2022 May 16, 2022	SELL	$5.31 - $8.7 $137,067 - $224,573	-25,813 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.51 - $10.81 $193,855 - $279,038	25,813 New	25,813 $221,000

Others Institutions Holding COGT

# of Institutions

159

Shares Held

114M

Call Options Held

104K

Put Options Held

163K

View Full List

About Cogent Biosciences, Inc.

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $717M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

More about COGT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account